Revance up on positive Daxi data in facial line study

 

• Revance Therapeutics (RVNC +6.7%) has announced positive efficacy and duration results from Phase 2 upper facial lines study, evaluating Daxibotulinumtoxin A for Injection in the combined treatment of glabellar lines, forehead lines and crow’s feet lines.
• The trial showed efficacy of none or mild wrinkle severity in at least 92% of subjects at week 4.
• Median time to return to baseline wrinkle severity was at least 33 weeks (7.6 months).
• Treatment with Daxibotulinumtoxin A for Injection was well tolerated across upper facial regions
• Revance is currently awaiting a decision on the approval of Daxibotulinumtoxin A for Injection for the treatment of glabellar lines by FDA, pending a manufacturing site inspection, which was delayed due to Covid-19 travel restrictions.
• https://seekingalpha.com/news/3645405-revance-stock-climbs-on-positive-daxi-data-in-facial-line-study